Phase 1 Two-way Drug Interaction Study of Deupirfenidone (LYT-100) and Nintedanib in Healthy Volunteers. ERS Congress. 2026. Molyneaux P, et al. [Oral Presentation]
Previous
Previous
Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026
Next
Next